Trial Profile
Efficacy of Lenalidomide in Patients with High-Risk Myelodysplastic Syndrome (Mds) Who Are Partially Resistant to Hypomethylating Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Jul 2018
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 26 Jul 2018 New trial record
- 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association